Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome

被引：0
|
作者：
Faderl, Stefan [1 ]
Garcia-Manero, Guillermo [1 ]
Estrov, Zeev [1 ]
Ravandi, Farhad [1 ]
Borthakur, Gautam [1 ]
Cortes, Jorge [1 ]
O'Brien, Susan [1 ]
Gandhi, Varsha [2 ]
Plunkett, William [2 ]
Byrd, Anna L. [1 ]
Kwari, Monica [1 ]
Kantarjian, Hagop [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Dev Therapeut, Houston, TX 77030 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：53 / 54
页数：2
相关论文
共 50 条
  • [1] Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi, Farhad
    Borthakur, Gautam
    Cortes, Jorge E.
    O'Brien, Susan
    Gandhi, Varsha
    Plunkett, William
    Byrd, Anna
    Kwari, Monica
    Kantarjian, Hagop M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2755 - 2760
  • [2] A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Ravandi, Farhad
    Borthakur, Gautam
    Estrov, Zeev
    Gandhi, Varsha
    Byrd, Anna L.
    Kwari, Monica
    Cortes, Jorge
    Kantarjian, Hagop M.
    [J]. CANCER, 2012, 118 (03) : 722 - 728
  • [3] Treatment of Higher-Risk Myelodysplastic Syndrome
    Garcia-Manero, Guillermo
    [J]. SEMINARS IN ONCOLOGY, 2011, 38 (05) : 673 - 681
  • [4] Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
    Sangmin Lee
    Sanjay Mohan
    Jessica Knupp
    Kamal Chamoun
    Adrienne de Jonge
    Fan Yang
    Erkan Baloglu
    Jatin Shah
    Michael G. Kauffman
    Sharon Shacham
    Bhavana Bhatnagar
    [J]. Journal of Hematology & Oncology, 15
  • [5] Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
    Lee, Sangmin
    Mohan, Sanjay
    Knupp, Jessica
    Chamoun, Kamal
    de Jonge, Adrienne
    Yang, Fan
    Baloglu, Erkan
    Shah, Jatin
    Kauffman, Michael G.
    Shacham, Sharon
    Bhatnagar, Bhavana
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [6] A RANDOMIZED STUDY OF DECITABINE ALTERNATING WITH CLOFARABINE VERSUS DECITABINE ALONE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Faderl, S.
    Garcia-Manero, G.
    Kadia, T.
    Borthakur, G.
    Jabbour, E.
    Ravandi, F.
    Estrov, Z.
    Cortes, J.
    Autry, J.
    Kantarjian, H.
    [J]. HAEMATOLOGICA, 2012, 97 : 369 - 369
  • [7] Decitabine treatment of patients with higher-risk myelodysplastic syndromes
    Steensma, David P.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S12 - S17
  • [8] Low Efficacy and High Mortality Associated with Clofarabine Treatment of Patients with Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes
    Roberts, Daniel A.
    Wadleigh, Martha
    McDonnell, Anne
    DeAngelo, Daniel J.
    Stone, Richard M.
    Steensma, David P.
    [J]. BLOOD, 2014, 124 (21)
  • [9] Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine
    Bouchla, Anthi
    Thomopoulos, Thomas P.
    Papageorgiou, Sotirios G.
    Apostolopoulou, Christina
    Loucari, Constantinos
    Mpazani, Efthimia
    Pappa, Vasiliki
    [J]. EPIGENOMICS, 2021, 13 (14) : 1129 - 1143
  • [10] Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks
    Pollyea, Daniel A.
    Gutman, Jonathan A.
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (04) : 421 - 431
12345